Logo Image
News|Articles|March 31, 2026

CCT Pledges Net Zero by 2050 as Industry Pressure to Decarbonize Intensifies

CCT’s 2050 Net Zero goal will tackle Scope 3 emissions, which make up the majority of Pharma’s carbon footprint.

Cold Chain Technologies (CCT) has announced a formal commitment to achieve Net Zero global emissions by 2050.1 This move signals a shift in the life sciences logistics sector, where the dual pressures of regulatory compliance and the high cost of temperature-related product loss are transforming sustainability from a corporate social responsibility initiative into a core business imperative.

What Is CCT’s Roadmap to Decarbonization?

CCT’s commitment highlights its role as a critical Scope 3 solutions provider for the pharmaceutical industry.1 Because Scope 3 emissions—those occurring in the indirect value chain—account for approximately 80% of a pharmaceutical firm’s total carbon footprint, the actions of logistics partners are pivotal to the industry meeting its broader climate goals.2

As part of its strategy, CCT is submitting specific targets for Science Based Targets initiative (SBTi) validation to ensure third-party accreditation for its progress.1 The company has already reported significant milestones, surpassing its internal landfill reduction target of 100 million pounds by 2025, reaching a total reduction of 147 million pounds to date.1

“We are dedicated to reducing the cold chain’s negative impact on the environment and helping the life science industry achieve a reduction in CO2 emissions, landfill waste, and more,” said Ranjeet Banerjee, chief executive officer of CCT in a release.1 “We are standing together with our customers to commit to sustainability and while we have made significant strides in the last few years, we intend to take our commitment to the next level, not only by making it public, but by submitting targets for SBTi validation.”1

What Are the Economic Stakes Behind Net Zero Emissions?

The timing of CCT’s commitment aligns with a period of explosive growth and high sensitivity in pharmaceutical logistics. The market, which is currently valued at $85 billion, is expected to grow at a compound annual growth rate of 8.6% by 2030, driven by the rise of cell and gene therapies, mRNA vaccines, GLP-1 therapies and more.2 These products require precise temperature control, leaving no room for error during transit.

Research indicates that temperature excursions and logistics mishaps cost the pharmaceutical industry an estimated $35 billion annually.2 This makes the transition to sustainable, digitally monitored packaging even more critical. CCT’s strategy involves leveraging digital applications to monitor shipments and alert customers of potential delays that could lead to product waste.1

“We believe our ecosystem of products, customer services and digital capabilities offers a sustainable advantage over alternative cold chain systems, and our commitment is to evidence this thoroughly using Science Based Targets and third-party accreditation,” Banerjee stated.1

How Does this Reflect Broader Industry Trends?

CCT’s focus on logistics decarbonization mirrors a broader industry trend toward tackling emissions in manufacturing and supply chain. Earlier this month, AstraZeneca, in partnership with ERM and Secaro, launched the Clean Heat Program to address industrial process heat—a primary barrier to progress that accounts for 18% of global greenhouse gas emissions.

While CCT focuses on the emissions of moving goods, the Clean Heat Program targets the manufacturing source. Preliminary data indicates that approximately 80% of a facility’s emissions are Scope 1, with 60% generated by natural gas. Much like the logistics sector, the manufacturing sector faces significant hurdles, as fewer than 10% of sites currently utilize renewable energy for direct heat.3

What Are the Regulatory Imperatives Behind Net Zero?

For the pharmaceutical industry, these sustainability initiatives are increasingly viewed through the lens of risk management. Evolving regulatory frameworks, such as the European Union’s Carbon Border Adjustment Mechanism and expanded SEC climate disclosure rules, are making low-carbon operations a prerequisite for global market access.3 To meet these mounting demands, suppliers are also moving away from single-use plastics toward recyclable and reusable parcel and pallet shippers.1

As personalized healthcare—a market expected to reach $3.18 trillion by 2025—continues to grow, the pressure on the logistics ecosystem will only intensify.2 To address upcoming climate challenges, CCT is prioritizing regional sourcing and delivery models to minimize transit-related emissions while pursuing authenticated, third-party assurance of its carbon reduction progress.1

References

Related Content